Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences' : Trademark Application for "LEAP EDUCATION AND ACCESS PROGRAM" Filed

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 11:57pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "LEAP EDUCATION AND ACCESS PROGRAM" by Gretchen R. Stroud, representing Gilead Sciences. This application was made available to the public on September 25, 2017 (see also Pharmaceutical Companies).

The serial number for this application is 85086605.

The international trademark goods and services class codes for this trademark application are 035 and 044. The applicant indicates that "Color is not claimed as a feature of the mark. The mark consists of a swirl design above the words 'LEAP EDUCATION AND ACCESS PROGRAM'."

As submitted by the applicant, this trademark application relates to the following goods and services:

• Assisting patients in enrolling in pharmaceutical reimbursement programs;

• Providing health information, namely, providing information about the treatment of pulmonary arterial hypertension.

The owner/registrar information for this application is: Gretchen R. Stroud, Gilead Sciences, 333 Lakeside Dr, Foster City, CA 94404-1147.

Keywords for this news article include: Pharmaceutical Companies, Trademarks, Gilead Sciences.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
10/12 GILEAD SCIENCES : An Application for the Trademark "NASH360" Has Been Filed by G..
10/12 GILEAD SCIENCES : High-Stakes Gilead Case Lands Fish & Richardson Principals Jua..
10/12 GILEAD SCIENCES : Completes Acquisition of Kite Pharma, Inc.
10/12 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/12 GILEAD SCIENCES : Presents Results From Phase 3 Study Evaluating Patients Who Sw..
10/12 GILEAD SCIENCES : Patent Issued for Co-Crystals, Salts and Solid Forms of Tenofo..
10/12 GILEAD SCIENCES : Announces New License Agreement With the Medicines Patent Pool..
10/12 Loncar Cancer Immunotherapy Index Announces Merger Replacements
More news
News from SeekingAlpha
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 GILEAD : My Only 'Buy 'Til You Die' Investment,  A Deep Due Diligence Dive
10/16 Q3 ROUNDUP : Top 5 Performing Knives
10/15 DIVIDEND INCOME UPDATE : September 2017
10/12 MONTHLY REVIEW OF DIVGRO : September 2017
Financials ($)
Sales 2017 25 905 M
EBIT 2017 16 060 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,61%
P/E ratio 2017 10,13
P/E ratio 2018 11,92
EV / Sales 2017 4,57x
EV / Sales 2018 5,04x
Capitalization 106 B
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,4 $
Spread / Average Target 3,9%
EPS Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.35%106 002
ACTELION23.24%29 919
GENMAB22.08%13 910
EXELIXIS, INC.66.06%7 277